Steven Shak Sells 1,500 Shares of Genomic Health, Inc. (GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 1,500 shares of the firm’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $78.18, for a total transaction of $117,270.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Steven Shak also recently made the following trade(s):

  • On Monday, September 10th, Steven Shak sold 5,500 shares of Genomic Health stock. The stock was sold at an average price of $63.05, for a total transaction of $346,775.00.

Shares of GHDX traded up $1.53 during mid-day trading on Thursday, hitting $75.50. The company had a trading volume of 475,170 shares, compared to its average volume of 294,643. Genomic Health, Inc. has a 1-year low of $26.54 and a 1-year high of $92.18. The stock has a market capitalization of $2.67 billion, a PE ratio of 7,550.00 and a beta of 0.40.

Genomic Health (NASDAQ:GHDX) last released its earnings results on Tuesday, November 6th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.28. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The business had revenue of $101.30 million for the quarter, compared to analysts’ expectations of $94.27 million. During the same period last year, the company earned ($0.06) earnings per share. The company’s quarterly revenue was up 23.2% on a year-over-year basis. On average, research analysts expect that Genomic Health, Inc. will post 1.06 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Globeflex Capital L P acquired a new stake in shares of Genomic Health in the second quarter worth approximately $116,000. Sun Life Financial INC acquired a new stake in shares of Genomic Health in the second quarter worth approximately $122,000. Pacer Advisors Inc. acquired a new stake in shares of Genomic Health in the third quarter worth approximately $171,000. Trexquant Investment LP acquired a new stake in shares of Genomic Health in the third quarter worth approximately $202,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Genomic Health in the second quarter worth approximately $162,000. 89.21% of the stock is currently owned by institutional investors and hedge funds.

GHDX has been the topic of several analyst reports. Raymond James initiated coverage on shares of Genomic Health in a research note on Tuesday, October 23rd. They set a “market perform” rating on the stock. Zacks Investment Research reaffirmed a “hold” rating on shares of Genomic Health in a research note on Tuesday, November 13th. BidaskClub raised shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 30th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $82.00 price target (up from $70.00) on shares of Genomic Health in a research note on Wednesday, November 7th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $48.33.

COPYRIGHT VIOLATION WARNING: “Steven Shak Sells 1,500 Shares of Genomic Health, Inc. (GHDX) Stock” was first published by WKRB News and is owned by of WKRB News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.wkrb13.com/2018/12/07/steven-shak-sells-1500-shares-of-genomic-health-inc-ghdx-stock.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Further Reading: Average Daily Trade Volume Explained

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply